Implications for Astellas as Medivation Invites Offers

Astellas: Pfizer Buying Medivation Is the Best Possible Outcome for the Japan Pharma Firm

Japan TMT Analyst

Pelham Smithers

Market Intel on Asian Tech with a Japan focus

Pelham Smithers Associates

Founded in 2009, Pelham Smithers Associates (PSA) provides market intelligence on Asian technology, focusing in particular on Japan. The industries covered by our team of specialists are: consumer electronics, telecomms, pharmaceuticals, internet, electronic parts and materials, automotive technology, retail and capital goods. 

Research is provided by the following:
Pelham Smithers: Macro, consumer electronics, telecoms & pharma
Joel Scheiman: Electronics materials / components
Julie Boote: Autos
Will Nestuk: Capital goods, machinery & transportation equipment parts
Thao Nguyen: eCommerce, internet content, marketing & advertising

Event-Driven

<p style="text-align: justify;">At first glance, <a href="https://www.smartkarma.com/entities/6091" target="_blank" data-smartkarma-citation="entities:6091:1">Astellas Pharma's</a> decision to buy closely-held Belgian biotech firm Ogeda for ¥90bil (US$800mil) is essentially a licensing deal dressed up as an acquisition. Ogeda has one meaningful asset, fezolinetant, which is in Phase II for hot flushes, and then several molecules in pre-clinical for a variety of disorders, including CNS. Paying US$800mil for a Phase II asset is by no means unusual, and by acquiring Ogeda, <a href="https://www.smartkarma.com/entities/6091" target="_blank" data-smartkarma-citation="entities:6091:1">Astellas</a> is relieved of any further milestone and royalty payments…</p>

At first glance, Astellas Pharma's decision to buy closely-held Belgian biotech firm Ogeda for ¥90bil (US$800mil) is essentially a licensing deal dressed up as an acquisition. Ogeda has one meaningful asset, fezolinetant, which is in Phase II for hot flushes, and then several molecules in pre-clinical for a variety of disorders, including CNS. Paying US$800mil for a Phase II asset is by no means unusual, and by acquiring Ogeda, Astellas is relieved of any further milestone and royalty payments…

Astellas (4503) Implications of Ogeda Acquisition